Jim Cramer's Stop Trading! Better Biotech

In the midst of a rout, Cramer notes Amgen's strength.
Publish date:

In the midst of a market rout, a gainer like


(AMGN) - Get Report

is worth investigating, Jim Cramer said on


"Stop Trading!" segment Friday.

"This is the first day Amgen hasn't gone down," Cramer noted. "Amgen now has a regular pharma multiple without any of the generic competition of the pharmas. The multiple contraction has been extraordinary in biotech. They're now trading like the


(PFE) - Get Report

and the


(MRK) - Get Report


Elsewhere, Cramer noted that


(MSFT) - Get Report



(CSCO) - Get Report

weren't trading badly Friday. "Perhaps you can divine from the tea leaves and say, 'They let us down, maybe they're trying to put in a bottom.' "

In retail, Cramer said, mid-tier department stores like

J.C. Penney

(JCP) - Get Report



(KSS) - Get Report

look like buys. "There's a trade going on which says people don't want to buy as much expensive stuff, but also don't want to go to


(WMT) - Get Report


Cramer praised

Rite Aid

(RAD) - Get Report

, noting increasing hedge fund interest in the name and "limited downside" at roughly $4.50 a share.

Regarding gold stocks, "This is day one of a selloff. Have you ever seen a group recover from day one of a selloff?"

Cramer was bearish on


(EXPE) - Get Report

, citing a "horrible" quarter. "They have a bad business model. They're really terrible."

At the time of publication, Cramer was long Microsoft.

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click

here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click

here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.